Avenue Therapeutics Inc (ATXI) USD0.0001

Sell:$0.76Buy:$0.76No change

Prices delayed by at least 15 minutes
Sell:$0.76
Buy:$0.76
Change:No change
Deal now
Prices delayed by at least 15 minutes
Sell:$0.76
Buy:$0.76
Change:No change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.

Key people

Alexandra Maclean
Chief Executive Officer, Director
David Jin
Interim Chief Financial Officer, Chief Operating Officer
Jay D. Kranzler
Non-Executive Chairman of the Board
Lindsay A. Rosenwald
Director
Faith L. Charles
Independent Director
Neil Herskowitz
Independent Director
Curtis Gale Oltmans
Independent Director
Click to see more

Key facts

  • Shares in issue
    3.18m
  • EPIC
    ATXI
  • ISIN
    US05360L4032
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $2.39m
  • Employees
    2
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.